Navigation Links
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
Date:6/3/2008

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that clinical data from three clinical trials of its anti-cancer drug nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, were presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 30 to June 3, 2008.

"The breadth of data presented at ASCO highlights the promise nimotuzumab holds for a diverse group of oncology patients," said David Allan, Chairman and CEO of YM BioSciences. "In each of these trials, results further demonstrated the unique potential for nimotuzumab to be an effective EGFR-targeting antibody without deleterious side-effects observed with the other drugs in its class."

"Phase III trial of nimotuzumab for the treatment of newly diagnosed

diffuse intrinsic pontine gliomas in children and adolescents" (Abstract

number 2058):

This poster reported data from a multi-centre Phase III study evaluating the feasibility and efficacy of nimotuzumab as the primary treatment for these patients. Between March 2006 and August 2007, 42 patients aged 3 to 16 years (median 7 years) were enrolled in this study, with 41 patients evaluable for response. The primary endpoint for the trial is median progression free survival at six months after diagnosis. Secondary endpoints include overall survival, response rate, toxicity and quality of life.

The poster presentation described preliminary results including that the median progression free survival was 5.9 months, that the median
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
5. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
8. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... PALO ALTO, Calif. , May 17, 2013 ... that it has achieved 50% enrollment of the ... trial to evaluate the safety and preliminary efficacy ... Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To ... Effect (SAE) reported. The Phase I ...
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says skin ... known to react more aggressively when hormones change, and acne ... other acne causing factors like P.acnes bacteria and excess dirt ... unsightly acne scars. Adult acne treatment, Probiotic Action shares new ... to reduce and prevent acne scarring. , In order to ...
(Date:5/17/2013)... 17, 2013 RURO Inc. is ... 4.1, a versatile refinement to the smart management ... improves its advanced methodical management for transgenic animal ... 4.1. The network-based platform provides user access with ... While continuing to emphasize streamlined tasks, such as ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... Inhibitor (human)] Commercial Launch --EXTON, Pa., Feb. 24 ViroPharma ... results for the fourth quarter and year ended December 31, ... , ... 2008; , Initiated commercial ...
... DiagnosticsSALT LAKE CITY, Feb. 24 Axial Biotech, ... development of molecular diagnostic technologies, announced today that ... management team as the company,s new Vice President ... directly to Kenneth Ward, M.D., Chairman and Chief ...
... 23 Smith & Nephew, Inc.,(NYSE: SNN ... the,introduction of VISIONAIRE Patient Matched instrumentation for use in ... that,uses a patient,s MRI and x-rays to create custom ... of high performance knee implants. , ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 12Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 3
(Date:5/16/2013)... developed at MIT may someday eliminate the need ... monitor their blood-sugar levels and inject themselves with ... glucose levels in the body and respond by ... the function of pancreatic islet cells, which are ... this type of system could ensure that blood-sugar ...
(Date:5/16/2013)... Philadelphia, PA, May 16, 2013 The relationship ... intelligence (IQ) has not been clear. Schizophrenia is ... functional disability. There are clues that reduced IQ ... schizophrenia. For example, reduced cognitive ability may precede ... may be present in healthy relatives of people ...
(Date:5/16/2013)... S.C. , May 16, 2013 ... in combination with a custom thin film transistor ... highest forensic quality roll image in the smallest ... today. Sherlock, an Appendix F Mobile ID FAP ... a 95% reduction in size and weight when ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Genetic risk for schizophrenia is connected to reduced IQ 2
... of 35 headwater basins in the United States and Canada ... rates was less than expected in many locations, suggesting that ... change. The study was just published in a special ... Long-Term Ecological Research (LTER) network of 26 sites around the ...
... Notre Dame,s Eck Institute for Global Health developed a ... drug resistance, an effort that will allow for real-time ... The new discovery is described in a paper appearing ... Science . The team of researchers includes Notre ...
... women will be diagnosed with breast cancer during her ... chance of successful treatment and long-term survival. However, early ... remains cumbersome, costly, and in many cases, cancer can ... based in the Dept. of Biomedical Engineering at McGill ...
Cached Biology News:Impact of warming climate doesn't always translate to streamflow 2Notre Dame researchers using novel method to combat malaria drug resistance 2Notre Dame researchers using novel method to combat malaria drug resistance 3Detecting breast cancer's fingerprint in a droplet of blood 2
... SilverQuest Silver Staining Kit is uniquely ... sensitivity with minimal protein modification for ... spectrometry problems associated with traditional silver ... kit because the reagents used do ...
...
... Insect Medium is formuatled for the ... Sf9 and Sf21 cells. Grace's Insect ... because it does not contain lactalbumin ... with transfection. Grace's Insect Medium, Supplemented ...
Schneider's Drosophila Medium is formulated for the expression of heterologous proteins in Drosophila S2 cells....
Biology Products: